Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Department of Nephrology, Monash Health, Monash Medical Centre, Clayton, Victoria, Australia.
Nephrol Dial Transplant. 2017 Sep 1;32(9):1558-1565. doi: 10.1093/ndt/gfw383.
There is evidence that end-stage kidney disease patients who are older or with more comorbidity may have a poor trade-off between benefits of dialysis and potential harms. We aimed to develop a tool for predicting patient mortality in the early stages of receiving dialysis.
In 23 658 patients aged 15+ years commencing dialysis between 2000 and 2009 in Australia and New Zealand a point score tool was developed to predict 6-month mortality based on a logistic regression analysis of factors available at dialysis initiation. Temporal validation used 2009-11 data from Australia and New Zealand. External validation used the UK Renal Registry.
Within 6 months of commencing dialysis 6.1% of patients had died. A small group (4.7%) of patients had a high predicted mortality risk (>20%), as predicted by the point score tool. Predictive variables were: older age, underweight, chronic lung disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease (particularly for patients <60 years of age), late referral to nephrologist care and underlying cause of renal disease. The new point score tool outperformed existing models, and had an area under the receiver operating characteristic curve of 0.755 on temporal validation with acceptable calibration and 0.713 on external validation with poor calibration.
Our point score tool for predicting 6-month mortality in patients at dialysis commencement has sufficient prognostic accuracy to use in Australia and New Zealand for prognosis and identification of high risk patients who may be given appropriate supportive care. Use in other countries requires further study.
有证据表明,老年或合并症较多的终末期肾病患者在透析的获益与潜在危害之间可能存在较差的权衡。我们旨在开发一种工具,用于预测接受透析早期患者的死亡率。
在澳大利亚和新西兰,2000 年至 2009 年间开始透析的 23658 名年龄在 15 岁以上的患者中,根据透析开始时可获得的因素的逻辑回归分析,开发了一种预测 6 个月死亡率的评分工具。使用澳大利亚和新西兰 2009-11 年的数据进行时间验证。使用英国肾脏登记处进行外部验证。
在开始透析后的 6 个月内,有 6.1%的患者死亡。一小部分(4.7%)患者的死亡风险预测值较高(>20%),这是评分工具预测的。预测变量包括:年龄较大、体重不足、慢性肺部疾病、冠状动脉疾病、外周血管疾病、脑血管疾病(特别是对于年龄<60 岁的患者)、晚期转至肾病医生治疗以及肾脏疾病的根本原因。新的评分工具优于现有模型,在时间验证中的受试者工作特征曲线下面积为 0.755,校准可接受,在外部验证中的曲线下面积为 0.713,校准较差。
我们用于预测开始透析时患者 6 个月死亡率的评分工具具有足够的预后准确性,可在澳大利亚和新西兰用于预后和识别高危患者,这些患者可能会得到适当的支持性护理。在其他国家/地区使用需要进一步研究。